Quick Answer
BridgeBio Oncology Therapeutics, Inc. reported Net Income of -$134.04 million for fiscal year 2025.
BridgeBio Oncology Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net Income | -$134.04M -80.5% |
-$74.28M -178051.7% |
-$41.7K | — |
| Diluted EPS | -$4.30 +99.9% |
-$5756.41 | — | — |
| Total Assets | $448.38M +172.9% |
$164.30M +49255.4% |
$332.9K | — |
| Cash and Equivalents | $373.69M +1111.3% |
$30.85M | — | — |
| Stockholders Equity | $411.10M +330.1% |
-$178.64M -54.5% |
-$115.64M -528496.2% |
-$21.9K |
| R&D Expense | $121.20M +65.8% |
$73.11M | — | — |
| Operating Income | -$145.82M -80.3% |
-$80.86M -193853.3% |
-$41.7K | — |
| Shares Outstanding | 79.99M +281412.5% |
28,415 | — | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$44.76M | -158.4% | -57.4% |
| Diluted EPS | September 30, 2025 | -$1.03 | +99.9% | +99.9% |
| Total Assets | September 30, 2025 | $484.79M | +152.1% | +145.6% |
| Cash and Equivalents | September 30, 2025 | $408.74M | — | +1224.9% |
| Stockholders Equity | September 30, 2025 | $446.70M | +380.6% | +296.2% |
| R&D Expense | September 30, 2025 | $35.05M | +95.9% | +95.9% |
| Operating Income | September 30, 2025 | -$49.18M | -150.1% | -4283.9% |
| Shares Outstanding | September 30, 2025 | 79.20M | — | +278614.4% |
- BridgeBio Oncology Therapeutics, Inc. reported Net Income of -$134.04 million for fiscal year 2025.
- BridgeBio Oncology Therapeutics, Inc. showed a decrease of -80.5% in Net Income compared to the prior fiscal year.
- BridgeBio Oncology Therapeutics, Inc. reported Diluted EPS of $4.30 per share (loss) for fiscal year 2025.
- BridgeBio Oncology Therapeutics, Inc. showed an increase of +99.9% in Diluted EPS compared to the prior fiscal year.
- BridgeBio Oncology Therapeutics, Inc. reported Total Assets of $448.38 million for fiscal year 2025.
- BridgeBio Oncology Therapeutics, Inc. showed an increase of +172.9% in Total Assets compared to the prior fiscal year.
- BridgeBio Oncology Therapeutics, Inc. reported Cash and Equivalents of $373.69 million for fiscal year 2025.
- BridgeBio Oncology Therapeutics, Inc. showed an increase of +1111.3% in Cash and Equivalents compared to the prior fiscal year.
- BridgeBio Oncology Therapeutics, Inc. reported Stockholders Equity of $411.10 million for fiscal year 2025.
- BridgeBio Oncology Therapeutics, Inc. showed an increase of +330.1% in Stockholders Equity compared to the prior fiscal year.
- BridgeBio Oncology Therapeutics, Inc. reported R&D Expense of $121.20 million for fiscal year 2025.
- BridgeBio Oncology Therapeutics, Inc. showed an increase of +65.8% in R&D Expense compared to the prior fiscal year.
- BridgeBio Oncology Therapeutics, Inc. reported Operating Income of -$145.82 million for fiscal year 2025.
- BridgeBio Oncology Therapeutics, Inc. showed a decrease of -80.3% in Operating Income compared to the prior fiscal year.
- BridgeBio Oncology Therapeutics, Inc. reported Shares Outstanding of 79.99 million shares for fiscal year 2025.
- BridgeBio Oncology Therapeutics, Inc. showed an increase of +281412.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: